Similarly, CD38 CAR T cells have been developed for the targeting of CD38+ multiple myeloma cells [122], but on-target/off-tumor effects limited its efficacy; thus, the development of lower potency CD38 CAR T cells has improved specific on-tumor effects [123]. This evidence concerns the gene CD38 and plasma cell myeloma.